Obesity and breast cancer: The role of dysregulated estrogen metabolism

Obesity and Breast Cancer: The Role of Dysregulated Estrogen Metabolism

Volumn , Issue , 2014, Pages 1-56

  Brown, Kristy A ^a   Simpson, Evan R ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84996625048     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4899-8002-1     Document Type: Book

References (221)

1. Heine, P. A., et al. (2000). Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 97(23), 12729-12734.
2. Jones, M. E., et al. (2000). Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proceedings of the National Academy of Sciences of the United States of America, 97(23), 12735-12740.
3. Van Sinderen, M. L., et al. (2009). The estrogenic component of tibolone reduces adiposity in female aromatase knockout mice. Menopause, 16(3), 582-588.
4. Toth, M. J., et al. (2000). Effect of menopausal status on body composition and abdominal fat distribution. International Journal of Obesity and Related Metabolic Disorders, 24(2), 226-231.
5. Teede, H. J., Lombard, C., & Deeks, A. A. (2010). Obesity, metabolic complications and the menopause: An opportunity for prevention. Climacteric, 13(3), 203-209.
6. Musatov, S., et al. (2007). Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 104(7), 2501-2506.
7. Brown, L. M., & Clegg, D. J. (2010). Central effects of estradiol in the regulation of food intake, body weight, and adiposity. The Journal of Steroid Biochemistry and Molecular Biology, 122(1-3), 65-73.
8. Mizutani, T., et al. (1994). Identification of estrogen receptor in human adipose tissue and adipocytes. The Journal of Clinical Endocrinology and Metabolism, 78(4), 950-954.
9. Lundholm, L., et al. (2008). Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertility and Sterility, 90(1), 44-48.
10. Price, T. M., et al. (1998). Estrogen regulation of adipose tissue lipoprotein lipase-possible mechanism of body fat distribution. American Journal of Obstetrics and Gynecology, 178(1 Pt 1), 101-107.
11. McInnes, K. J., et al. (2012). Regulation of LKB1 expression by sex hormones in adipocytes. International Journal of Obesity (London), 36(7), 982-985.
12. McInnes, K. J., et al. (2006). Regulation of adenosine 5', monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state. Endocrinology, 147(12), 5907-5913.
13. D'Eon, T. M., et al. (2005). Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. Journal of Biological Chemistry, 280(43), 35983-35991.
14. Vieira Potter, V. J., et al. (2012). Adipose tissue inflammation and reduced insulin sensitivity in ovariectomized mice occurs in the absence of increased adiposity. Endocrinology, 153(9), 4266-4277.
15. Ghisletti, S., et al. (2005). 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Molecular and Cellular Biology, 25(8), 2957-2968.
16. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. (2004). Lancet 363(9403), 157-163.
17. World Health Organisation. (2012). Obesity and overweight. Fact sheet No 311. Retrieved from http://www.who.int/mediacentre/factsheets/fs311/en/#.
18. Garrisi, V. M., et al. (2012). Body mass index and serum proteomic profile in breast cancer and healthy women: A prospective study. PLoS ONE, 7(11), e49631.
19. Kamineni, A., et al. (2012). Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes and Control, 24, 305-312.
20. Biglia, N., et al. (2012). Body mass index (BMI) and breast cancer: Impact on tumor histopatologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecological Endocrinology.
21. Zhang, F. F., et al. (2012). Total energy intake and breast cancer risk in sisters: The Breast Cancer Family Registry. Breast Cancer Research and Treatment
22. van Kruijsdijk, R. C., van der Wall, E., & Visseren, F. L. (2009). Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiology, Biomarkers and Prevention, 18(10), 2569-2578.
23. Cheraghi, Z., et al. (2012). Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis. PLoS ONE, 7(12), e51446.
24. Bergstrom, A., et al. (2001). Overweight as an avoidable cause of cancer in Europe. International Journal of Cancer, 91(3), 421-430.
25. Ursin, G., et al. (1995). A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology, 6(2), 137-141.
26. Lahmann, P. H., et al. (2004). Body size and breast cancer risk: Findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 111(5), 762-771.
27. Weiderpass, E., et al. (2004). A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiology, Biomarkers and Prevention, 13(7), 1121-1127.
28. Michels, K. B., Terry, K. L., & Willett, W. C. (2006). Longitudinal study on the role of body size in premenopausal breast cancer. Archives of Internal Medicine, 166(21), 2395-2402.
29. Pierobon, M., & Frankenfeld, C. L. (2013). Obesity as a risk factor for triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Research and Treatment, 137(1), 307-314.
30. Ricks-Santi, L. J., et al. (2013). BRCA1 polymorphisms and breast cancer epidemiology in the Western New York Exposures and Breast cancer (WEB) study. Genetic Epidemiology, 37(5), 504-511.
31. Key, T. J., et al. (2003). Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. The Journal of the National Cancer Institute, 95(16), 1218-26.
32. Kimura, K., et al. (2012). Association between body mass index and breast cancer intrinsic subtypes in Japanese women. Experimental and Therapeutic Medicine, 4(3), 391-396.
33. John, E. M., Phipps, A. I., & Sangaramoorthy, M. (2013). Body size, modifying factors, and postmenopausal breast cancer risk in a multiethnic population: The San Francisco bay area breast cancer study. Springerplus, 2(1), 239.
34. Krishnan, K., et al. (2013). Associations between weight in early adulthood, change in weight and breast cancer risk in postmenopausal women. Cancer Epidemiology Biomarkers & Prevention.
35. Boyd, N. F., et al. (2011). Mammographic density and breast cancer risk: Current understanding and future prospects. Breast Cancer Research, 13(6), 223.
36. Dorgan, J. F., et al. (2012). Height, adiposity and body fat distribution and breast density in young women. Breast Cancer Research, 14(4), R107.
37. Boyd, N. F., et al. (1998). The relationship of anthropometric measures to radiological features of the breast in premenopausal women. British Journal of Cancer, 78(9), 1233-8.
38. Vachon, C. M., et al. (2010). Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Research and Treatment, 125, 243-252 (Epub ahead of print).
39. Fuhrman, B. J., et al. (2012). Estrogen metabolism and mammographic density in postmenopausal women: A cross-sectional study. Cancer Epidemiology, Biomarkers and Prevention, 21(9), 1582-1591.
40. Amadou, A., et al. (2013). Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: A systematic review and dose-response meta-analysis. Obesity Reviews.
41. Abdullah, A., et al. (2010). The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies. Diabetes Research and Clinical Practice, 89(3), 309-319.
42. Forte, V., et al. (2012). Obesity, diabetes, the cardiorenal syndrome, and risk for cancer. Cardiorenal Medicine, 2(2), 143-162.
43. Almdal, T., et al. (2004). The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with years of follow-up. Archives of Internal Medicine, 164(13), 1422-1426.
44. Seshasai, S. R., et al. (2011). Diabetes mellitus, fasting glucose, and risk of cause-specific death. New England Journal of Medicine, 364(9), 829-841.
45. Boyle, P., et al. (2012). Diabetes and breast cancer risk: A meta-analysis. British Journal of Cancer, 107(9), 1608-1617.
46. Yu, Z. G., et al. (2012). The prevalence and correlates of breast cancer among women in Eastern China. PLoS ONE, 7(6), e37784.
47. Esposito, K., et al. (2013). Metabolic syndrome and postmenopausal breast cancer: Systematic review and meta-analysis. Menopause.
48. Kusano, A. S., et al. (2006). A prospective study of breast size and premenopausal breast cancer incidence. International Journal of Cancer, 118(8), 2031-2034.
49. Markkula, A., et al. (2012). Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes and Control, 23(8), 1307-1316.
50. Druesne-Pecollo, N., et al. (2012). Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Research and Treatment, 135(3), 647-654.
51. Liu, Y. L., et al. (2012). Association of serum lipid profile with distant metastasis in breast cancer patients. Zhonghua Zhong Liu Za Zhi, 34(2), 129-131.
52. Forsythe, L. P., et al. (2012). Pain in long-term breast cancer survivors: The role of body mass index, physical activity, and sedentary behavior. Breast Cancer Research and Treatment.
53. Campbell, P. T., et al. (2012). Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care, 35(9), 1835-1844.
54. Lehr, S., et al. (2012). Identification and validation of novel adipokines released from primary human adipocytes. Molecular & Cellular Proteomics, 11(1), M111 010504.
55. Ryan, A. S., et al. (2003). Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care, 26(8), 2383-2388.
56. Kelesidis, I., Kelesidis, T., & Mantzoros, C. S. (2006). Adiponectin and cancer: A systematic review. British Journal of Cancer, 94(9), 1221-1225.
57. Gulcelik, M. A., et al. (2012). Associations between adiponectin and two different cancers: Breast and colon. Asian Pacific Journal of Cancer Prevention, 13(1), 395-398.
58. Rajala, M. W., & Scherer, P. E. (2003). Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology, 144(9), 3765-3773.
59. Rose, D. P., Komninou, D., & Stephenson, G. D. (2004). Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Review, 5(3), 153-165.
60. Wu, M.-H., et al. (2009). Circulating levels of leptin, adiposity and breast cancer risk. British Journal of Cancer, 100, 578-582.
61. Maccio, A., et al. (2010). Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: Preliminary results and therapeutic implications. Journal of Molecular Medicine (Berlin), 88(7), 677-686.
62. Grossmann, M. E., et al. (2010). Obesity and breast cancer: Status of leptin and adiponectin in pathological processes. Cancer and Metastasis Reviews, 29(4), 641-653.
63. Cirillo, D., et al. (2008). Leptin signaling in breast cancer: An overview. Journal of Cellular Biochemistry, 105(4), 956-964.
64. Jarde, T., et al. (2011). Molecular mechanisms of leptin and adiponectin in breast cancer. European Journal of Cancer, 47(1), 33-43.
65. Xue, R. Q., et al. (2012). Effects of exogenous human leptin on heat shock protein 70 expression in MCF-7 breast cancer cells and breast carcinoma of nude mice xenograft model. Chinese Medical Journal (English Edition), 125(4), 680-686.
66. Barnes, J. A., et al. (2001). Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress and Chaperones, 6(4), 316-325.
67. Zheng, Q., Hursting, S. D., & Reizes, O. (2012). Leptin regulates cyclin D1 in luminal epithelial cells of mouse MMTV-Wnt-1 mammary tumors. Journal of Cancer Research and Clinical Oncology, 138(9), 1607-1612.
68. Dalamaga, M. (2012). Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Medical Hypotheses, 79(5), 617-621.
69. Lee, Y. C., et al. (2012). Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecologic Oncology, 125(3), 742-750.
70. Llanos, A. A., et al. (2012). Adipokines in plasma and breast tissues: Associations with breast cancer risk factors. Cancer Epidemiology, Biomarkers & Prevention, 21(10), 1745-1755.
71. Simons, P. J., et al. (2005). Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: Evidence that tumor necrosis factor-alpha- and interleukin-1beta-treated human preadipocytes are potent leptin producers. Cytokine, 32(2), 94-103.
72. Vona-Davis, L., & Rose, D. P. (2009). Angiogenesis, adipokines and breast cancer. Cytokine & Growth Factor Reviews, 20(3), 193-201.
73. Zeyda, M., et al. (2010). Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. International Journal of Obesity (London), 34(12), 1684-1694.
74. Subbaramaiah, K., et al. (2011). Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevention Research (Philadelphia), 4(3), 329-346.
75. Subbaramaiah, K., et al. (2012). Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discovery, 2(4), 356-365.
76. Chen, J. (2011). Multiple signal pathways in obesity-associated cancer. Obesity Reviews, 12(12), 1063-1070.
77. Cannata, D., et al. (2010). Type 2 diabetes and cancer: What is the connection? Mount Sinai Journal of Medicine, 77(2), 197-213.
78. Chong, Y. M., et al. (2006). The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent noncancerous tissue. Breast Cancer Research and Treatment, 99(3), 275-288.
79. Rice, M. S., et al. (2012). Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. Breast Cancer Research and Treatment, 136(3), 805-812.
80. McNatty, K. P., et al. (1976). Concentration of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. Journal of Endocrinology, 71(1), 77-85.
81. Fournet-Dulguerov, N., et al. (1987). Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiotrophoblast of the human placenta. Journal of Clinical Endocrinology and Metabolism, 65(4), 757-764.
82. Grodin, J. M., Siiteri, P. K., & MacDonald, P. C. (1973). Source of estrogen production in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 36(2), 207-214.
83. Hemsell, D. L., et al. (1974). Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. Journal of Clinical Endocrinology and Metabolism, 38(3), 476-479.
84. Edman, C. D., & MacDonald, P. C. (1978). Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women. American Journal of Obstetrics and Gynecology, 130(4), 456-461.
85. Miller, W. R., & O'Neill, J. (1987). The importance of local synthesis of estrogen within the breast. Steroids, 50(4-6), 537-548.
86. Nimrod, A., & Ryan, K. J. (1975). Aromatization of androgens by human abdominal and breast fat tissue. Journal of Clinical Endocrinology and Metabolism, 40(3), 367-372.
87. Thompson, E. A., Jr. & Siiteri, P. K., (1974) Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. Journal of Biological Chemistry, 249(17), 5364-5372.
88. Ghosh, D., et al. (2009). Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature, 457(7226), 219-223.
89. Hankinson, S. E., et al. (1998). Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute, 90(17), 1292-1299.
90. Huang, Z., et al. (1997). Dual effects of weight and weight gain on breast cancer risk. The Journal of the American Medical Association, 278(17), 1407-1411.
91. Haynes, B. P., et al. (2010). Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research, 16(6), 1790-1801.
92. O'Neill, J. S., Elton, R. A., & Miller, W. R. (1988). Aromatase activity in adipose tissue from breast quadrants: A link with tumour site. British Medical Journal (Clinical Research Ed), 296(6624), 741-743.
93. Bulun, S. E., et al. (1993). A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. Journal of Clinical Endocrinology and Metabolism, 77(6), 1622-1628.
94. Utsumi, T., et al. (1996). Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. Journal of Clinical Endocrinology and Metabolism, 81(6), 2344-2349.
95. Zhou, C., et al. (1996). Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. Journal of Steroid Biochemistry and Molecular Biology, 59(2), 163-171.
96. Sasano, H., et al. (1994). Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathology, 25(5), 530-535.
97. Harada, N., Utsumi, T., & Takagi, Y. (1993). Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11312-11316.
98. Tekmal, R. R., et al. (1999). Aromatase overexpression and breast hyperplasia, an in vivo model-continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocrine-Related Cancer, 6(2), 307-314.
99. Ackerman, G. E., et al. (1981). Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. Journal of Clinical Endocrinology and Metabolism, 53(2), 412-417.
100. Santen, R. J., et al. (1994). Stromal spindle cells contain aromatase in human breast tumors. Journal of Clinical Endocrinology and Metabolism, 79(2), 627-632.
101. Sasano, H., et al. (1996). Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. Journal of Clinical Endocrinology and Metabolism, 81(11), 4042-4046.
102. Brodie, A., Long, B., & Lu, Q., (1998). Aromatase expression in the human breast. Breast Cancer Research and Treatment, 49(Suppl 1), S85-S91 (discussion S109-19).
103. Kumar, P., & Mendelson, C. R. (2011). Estrogen-related receptor gamma (ERRgamma) mediates oxygen-dependent induction of aromatase (CYP19) gene expression during human trophoblast differentiation. Molecular Endocrinology, 25(9), 1513-1526.
104. Evans, C. T., et al. (1986). Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proceedings of the National Academy of Sciences of the United States of America, 83(17), 6387-6391.
105. Corbin, C. J., et al. (1988). Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proceedings of the National Academy of Sciences of the United States of America, 85(23), 8948-8952.
106. Harada, N. (1988). Cloning of a complete cDNA encoding human aromatase: Immunochemical identification and sequence analysis. Biochemical and Biophysical Research Communications, 156(2), 725-732.
107. Chen, S. A., et al. (1988). Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA, 7(1), 27-38.
108. Means, G. D., et al. (1989). Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. Journal of Biological Chemistry, 264(32), 19385-19391.
109. Mendelson, C. R., et al. (1990). Use of molecular probes to study regulation of aromatase cytochrome P-450. Biology of Reproduction, 42(1), 1-10.
110. Tsuboi, H., et al. (2004). Prostanoid EP4 receptor is involved in suppression of 3T3-L1 adipocyte differentiation. Biochemical and Biophysical Research Communications, 322(3), 1066-1072.
111. Kawakami, M., et al. (1989). Cachectin/TNF kills or inhibits the differentiation of 3T3-L1 cells according to developmental stage. Journal of Cellular Physiology, 138(1), 1-7.
112. Kawashima, I., et al. (1991). Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FEBS Letters, 283(2), 199-202.
113. Clyne, C. D., et al. (2002). Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. Journal of Biological Chemistry, 277(23), 20591-20597.
114. Dieudonne, M. N., et al. (2006). Sex steroids and leptin regulate 11beta-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: Sex specificities. Journal of Steroid Biochemistry and Molecular Biology, 99(4-5), 189-196.
115. Simpson, E. R., et al. (1981). Estrogen formation in stromal cells of adipose tissue of women: Induction by glucocorticosteroids. Proceedings of the National Academy of Sciences of the United States of America, 78(9), 5690-5694.
116. Mendelson, C. R., et al. (1982). Regulation of aromatase activity of stromal cells derived from human adipose tissue. Endocrinology, 111(4), 1077-1085.
117. Simpson, E. R., et al. (1989). Regulation of estrogen biosynthesis by human adipose cells. Endocrine Reviews, 10(2), 136-148.
118. Mahendroo, M. S., Mendelson, C. R., & Simpson, E. R. (1993). Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. Journal of Biological Chemistry, 268(26), 19463-19470.
119. Agarwal, V. R., et al. (1997). Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. Journal of Clinical Endocrinology and Metabolism, 82(1), 70-74.
120. Agarwal, V. R., et al. (1996). Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Journal of Clinical Endocrinology and Metabolism, 81(11), 3843-3849.
121. Zhao, Y., et al. (1997). Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. Journal of Steroid Biochemistry and Molecular Biology, 61(3-6), 203-210.
122. Irahara, N., et al. (2006). Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. International Journal of Cancer, 118(8), 1915-1921.
123. Zhao, Y., Mendelson, C. R., & Simpson, E. R. (1995). Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Molecular Endocrinology, 9(3), 340-349.
124. Half, E., et al. (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Research, 62(6), 1676-1681.
125. Richards, J. A., & Brueggemeier, R. W. (2003). Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. Journal of Clinical Endocrinology and Metabolism, 88(6), 2810-2816.
126. Zhao, Y., et al. (1996). Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology, 137(12), 5739-5742.
127. Michael, M. D., Michael, L. F., & Simpson, E. R. (1997). A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene. Molecular and Cellular Endocrinology, 134(2), 147-156.
128. Zhou, D., & Chen, S. (1999). Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. Archives of Biochemistry and Biophysics, 371(2), 179-190.
129. Sofi, M., et al. (2003). Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. Breast Cancer Research and Treatment, 79(3), 399-407.
130. Subbaramaiah, K., et al. (2008). EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. Journal of Biological Chemistry, 283(6), 3433-3444.
131. Conkright, M. D., et al. (2003). TORCs: Transducers of regulated CREB activity. Molecular Cell, 12(2), 413-23.
132. Brown, K. A., et al. (2009). Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Research, 69(13), 5392-5399.
133. Samarajeewa, N. U., et al. (2013) CREB-regulated transcription co-activator family stimulates promoter II-driven aromatase expression in preadipocytes. Hormones and Cancer.
134. Koo, S. H., et al. (2005). The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature, 437(7062), 1109-1111.
135. Steinberg, G. R., & Kemp, B. E. (2009). AMPK in health and disease. Physiological Reviews, 89(3), 1025-1078.
136. Towler, M. C., & Hardie, D. G. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research, 100(3), 328-341.
137. Oakhill, J. S., et al. (2011). AMPK is a direct adenylate charge-regulated protein kinase. Science, 332(6036), 1433-1435.
138. Hurley, R. L., et al. (2006). Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. Journal of Biological Chemistry, 281(48), 36662-36672.
139. Hemminki, A., et al. (1998). A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature, 391(6663), 184-187.
140. Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006). LKB1-dependent signaling pathways. Annual Review of Biochemistry, 75, 137-163.
141. Coen, P., et al. (1991). An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. New England Journal of Medicine, 324(5), 317-322.
142. Bulun, S. E., et al. (1994). Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads. Journal of Clinical Endocrinology and Metabolism, 78(2), 1616-1621.
143. Schonwasser, D. C., et al. (1998). Activation of the mitogen-activated protein kinase/ extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Molecular and Cellular Biology, 18(2), 790-798.
144. Zhang, B., et al. (2004). JNK signaling involved in the effects of cyclic AMP on IL-1beta plus IFNgamma-induced inducible nitric oxide synthase expression in hepatocytes. Cellular Signalling, 16(7), 837-846.
145. Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103(2), 239-252.
146. Roux, P. P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68(2), 320-344.
147. Chen, D., et al. (2007). Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts. Cancer Research, 67(18), 8914-8922.
148. Mechta-Grigoriou, F., Gerald, D., & Yaniv, M. (2001). The mammalian Jun proteins: Redundancy and specificity. Oncogene, 20(19), 2378-2389.
149. Chen, D., et al. (2011). JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters. Molecular Endocrinology, 25(5), 767-775.
150. Zhou, J., et al. (2005). Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Research, 65(2), 657-663.
151. Chand, A. L., et al. (2011). Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts. Steroids, 76(8), 741-744.
152. Kovacic, A., et al. (2004). Inhibition of aromatase transcription via promoter II by short heterodimer partner in human preadipocytes. Molecular Endocrinology, 18(1), 252-259.
153. Bouchard, M. F., Taniguchi, H., & Viger, R. S. (2005). Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells. Endocrinology, 146(11), 4905-4916.
154. Safi, R., et al. (2005). Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Research, 65(24), 11762-11770.
155. Liu, X. H., et al. (2002). Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. Journal of Biological Chemistry, 277(51), 50081-50086.
156. Fukuda, R., Kelly, B., & Semenza, G. L. (2003). Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxiainducible factor 1. Cancer Research, 63(9), 2330-2334.
157. Samarajeewa, N. U., et al. (2013). HIF-1alpha stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Research, 15(2), R30.
158. Hu, Y., et al. (2005). Modulation of aromatase expression by BRCA1: A possible link to tissue-specific tumor suppression. Oncogene, 24(56), 8343-8348.
159. Lu, M., et al. (2006). BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. Journal of Clinical Endocrinology and Metabolism, 91(11), 4514-4519.
160. Ghosh, S., et al. (2007). Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. American Journal of Physiology: Endocrinology and Metabolism, 292(1), E246-E252.
161. Chand, A. L., Simpson, E. R., & Clyne, C. D. (2009). Aromatase expression is increased in BRCA1 mutation carriers. BMC Cancer, 9, 148.
162. Yang, C., Zhou, D., & Chen, S. (1998). Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Research, 58(24), 5695-5700.
163. Yang, C., et al. (2002). Regulation of aromatase promoter activity in human breast tissue by nuclear receptors. Oncogene, 21(18), 2854-2863.
164. Okubo, T., et al. (2001). Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Research, 61(4), 1338-1346.
165. Catalano, S., et al. (2003). Leptin enhances, via AP-1, expression of aromatase in the MCF-cell line. Journal of Biological Chemistry, 278(31), 28668-28676.
166. Dieudonne, M. N., et al. (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochemical and Biophysical Research Communications, 345(1), 271-279.
167. Singh, A., et al. (1995). IL-6sR: Release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. Journal of Endocrinology, 147(2), R9-R12.
168. Macdiarmid, F., et al. (1994). Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha. Molecular and Cellular Endocrinology, 106(1-2), 17-21.
169. Zhao, Y., et al. (1996). Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Molecular Endocrinology, 10(11), 1350-1357.
170. To, S. Q., et al. (2013). Involvement of early growth response factors in TNF-alpha-induced aromatase expression in breast adipose. Breast Cancer Research and Treatment.
171. To, S. Q., Knower, K. C., & Clyne, C. D. (2013). NF-kappaB and MAPK signalling pathways mediate TNF-alpha-induced early growth response gene transcription leading to aromatase expression. Biochemical and Biophysical Research Communications, 433(1), 96-101.
172. Deb, S., et al. (2004). Estrogen regulates expression of tumor necrosis factor receptors in breast adipose fibroblasts. Journal of Clinical Endocrinology and Metabolism, 89(8), 4018-4024.
173. Mendelson, C. R., et al. (1986). Growth factors suppress and phorbol esters potentiate the action of dibutyryl adenosine 3',5'-monophosphate to stimulate aromatase activity of human adipose stromal cells. Endocrinology, 118(3), 968-973.
174. Lueprasitsakul, P., Latour, D., & Longcope, C. (1990). Aromatase activity in human adipose tissue stromal cells: Effect of growth factors. Steroids, 55(12), 540-544.
175. Schmidt, M., & Loffler, G. (1994). Induction of aromatase in stromal vascular cells from human breast adipose tissue depends on cortisol and growth factors. FEBS Letters, 341(2-3), 177-181.
176. Su, B., et al. (2011). Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms. Journal of Steroid Biochemistry and Molecular Biology, 123(3-5), 101-108.
177. Zhou, J., et al. (2001). Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: An epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Research, 61(5), 2328-2334.
178. Sparano, J. A., et al. (2012). Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer, 118(23), 5937-5946.
179. Chen, S., et al. (2012). Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS ONE, 7(7), e41380.
180. Sendur, M. A., et al. (2012). Efficacy of adjuvant aromatase inhibitor in hormone receptorpositive postmenopausal breast cancer patients according to the body mass index. British Journal of Cancer, 107(11), 1815-1819.
181. Ewertz, M., et al. (2012). Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. Journal of Clinical Oncology, 30(32), 3967-3975.
182. Suzuki, R., Saji, S., & Toi, M. (2012). Impact of body mass index on breast cancer in accordance with the life-stage of women. Front Oncol, 2, 123.
183. Pfeiler, G., et al. (2013). Efficacy of tamoxifen+/-aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: An analysis of 1509 patients of the ABCSG-06 trial. British Journal of Cancer, 108(7), 1408-1414.
184. Sestak, I., et al. (2010). Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. Journal of Clinical Oncology, 28(21), 3411-3415.
185. Wolters, R., et al. (2012). Endocrine therapy in obese patients with primary breast cancer: Another piece of evidence in an unfinished puzzle. Breast Cancer Research and Treatment, 131(3), 925-931.
186. Folkerd, E. J., et al. (2012). Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. Journal of Clinical Oncology, 30(24), 2977-2980.
187. Diorio, C., et al. (2012). Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Research and Treatment, 136(2), 573-579.
188. Harvie, M., & Howell, A. (2006). Energy balance adiposity and breast cancer-energy restriction strategies for breast cancer prevention. Obesity Reviews, 7(1), 33-47.
189. Cleary, M. P., et al. (2002). Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice. Cancer Epidemiology, Biomarkers & Prevention, 11(9), 836-843.
190. Jones, S. B., et al. (2012). Effect of exercise on markers of inflammation in breast cancer survivors: The Yale exercise and survivorship study. Cancer Prevention Research (Philadelphia).
191. Lof, M., Bergstrom, K., & Weiderpass, E. (2012). Physical activity and biomarkers in breast cancer survivors: A systematic review. Maturitas, 73(2), 134-142.
192. Jones, M. E., et al. (2013). Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index. The Journal of Clinical Endocrinology & Metabolism.
193. Esposito, K., et al. (2003). Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. The Journal of the American Medical Association, 289(14), 1799-1804.
194. Dandona, P., et al. (1998). Tumor necrosis factor-alpha in sera of obese patients: Fall with weight loss. Journal of Clinical Endocrinology and Metabolism, 83(8), 2907-2910.
195. Bastard, J. P., et al. (2000). Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. Journal of Clinical Endocrinology and Metabolism, 85(9), 3338-3342.
196. Cancello, R., et al. (2005). Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes, 54(8), 2277-2286.
197. Ashrafian, H., et al. (2011). Metabolic surgery and cancer: Protective effects of bariatric procedures. Cancer, 117(9), 788-799.
198. Christou, N. V., et al. (2008). Bariatric surgery reduces cancer risk in morbidly obese patients. Surgery for Obesity and Related Diseases, 4(6), 691-695.
199. Bodmer, M., et al. (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care, 33(6), 1304-1308.
200. Beck, E., & Scheen, A. J. (2010). (Anti-cancer activity of metformin: New perspectives for an old drug). Rev Med Suisse 6(260), 1601-1607.
201. Niraula, S., et al. (2012). Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment, 135(3), 821-830.
202. Rena, G., Pearson, E. R., & Sakamoto, K. (2013). Molecular mechanism of action of metformin: Old or new insights? Diabetologia, 56, 1898-1906.
203. Buzzai, M., et al. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research, 67(14), 6745-6752.
204. Zhuang, Y., & Miskimins, W. K. (2008). Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of Molecular Signaling, 3, 18.
205. Ben Sahra, I., et al. (2010). Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Research, 70(6), 2465-2475.
206. Phoenix, K. N., Vumbaca, F., & Claffey, K. P. (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Research and Treatment, 113(1), 101-111.
207. Dowling, R. J., et al. (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research, 67(22), 10804-10812.
208. Brown, K. A., et al. (2010). Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research and Treatment, 123(2), 591-596.
209. Samarajeewa, N. U., et al. (2011). Promoter-specific effects of metformin on aromatase transcript expression. Steroids, 76(8), 768-771.
210. Rubin, G. L., et al. (2000). Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy. Cancer Research, 60(6), 1604-1608.
211. Rubin, G. L., et al. (2002). Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology, 143(8), 2863-2871.
212. Chand, A. L., et al. (2010). The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. Endocrine-Related Cancer, 17(4), 965-975.
213. Thiruchelvam, P. T., et al. (2011). The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Research and Treatment, 127(2), 385-396.
214. Chand, A. L., et al. (2012). The orphan nuclear receptor LRH-1 and ERalpha activate GREB1 expression to induce breast cancer cell proliferation. PLoS ONE, 7(2), e31593.
215. Busby, S., et al. (2010). Discovery of Inverse Agonists for the Liver Receptor Homologue-1 (LRH1; NR5A2), in Probe Reports from the NIH Molecular Libraries Program, Bethesda, MD.
216. Purohit, A., et al. (1999). Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochemical and Biophysical Research Communications, 261(1), 214-217.
217. Deb, S., et al. (2006). A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts. Journal of Biological Chemistry, 281(5), 2585-2597.
218. Alvarez-Garcia, V., et al. (2012). Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. Journal of Pineal Research, 52(3), 282-290.
219. Knower, K. C., et al. (2012). Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Research and Treatment, 132(2), 765-771.
220. Diaz-Cruz, E. S., Shapiro, C. L., & Brueggemeier, R. W. (2005). Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. Journal of Clinical Endocrinology and Metabolism, 90(5), 2563-2570.
221. Brueggemeier, R. W., et al. (2005). Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 95(1-5), 129-136.